Phio Pharmaceuticals
PHIO
7 hedge funds and large institutions have $647K invested in Phio Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.
150% more capital invested
Capital invested by funds: $259K → $647K (+$388K)
0% more funds holding
Funds holding: 7 → 7 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$55.1K |
| 2 |
VF
Virtu Financial
New York
|
+$18.4K |
| 3 |
SG Americas Securities
New York
|
+$16.1K |
| 4 |
HSBC Holdings
London,
United Kingdom
|
+$5.74K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$26K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $427K | +$3.45K | +3 | +60% |
|
|
2
SG Americas Securities
New York
| $135K | +$16.1K | +14 | +12% |
|
|
3
Renaissance Technologies
New York
| $57K | +$55.1K | +48 | +600% |
|
|
VF
4
Virtu Financial
New York
| $17K | +$18.4K | +16 | New |
|
5
Vanguard Group
Malvern,
Pennsylvania
| $5K | – | – | – |
|
|
6
HSBC Holdings
London,
United Kingdom
| $5K | +$5.74K | +5 | New |
|
7
Morgan Stanley
New York
| $1K | – | – | – |
|
|
KFS
8
Kelly Financial Services
Braintree,
Massachusetts
| $1 | – | – | – |
|
|
CH
9
CVI Holdings
Wilmington,
Delaware
| – | -$26K | -16 | Closed |
|
|
10
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$9K | -6 | Closed |
|
PHIO Hedge Fund Activity: Q4 2019 in Review
7 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2019, worth a combined $647K — up 150% from $259K a quarter earlier.
Fund positioning in PHIO was balanced in Q4 2019: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $55.1K. The largest seller was CVI Holdings, exiting entirely with an estimated $26K sold.
- 7 institutional investors held Phio Pharmaceuticals (PHIO) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $647K of Phio Pharmaceuticals stock for Q4 2019, up 150% quarter-over-quarter.
- 2 funds opened new Phio Pharmaceuticals positions in Q4 2019 and 2 closed out, a net change of 0 holders.
- The largest Phio Pharmaceuticals buyer in Q4 2019 was Renaissance Technologies, an estimated $55.1K added.
- The largest Phio Pharmaceuticals seller in Q4 2019 was CVI Holdings, an estimated $26K sold.
Based on aggregated 13F filings for Q4 2019.